Anastrozole
- Generic Name
- Anastrozole
- Brand Names
- Arimidex
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N5
- CAS Number
- 120511-73-1
- Unique Ingredient Identifier
- 2Z07MYW1AZ
- Background
Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated ad...
- Indication
Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in...
- Associated Conditions
- Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Gruppo Italiano Mammella (GIM)
- Target Recruit Count
- 3697
- Registration Number
- NCT00541086
- Locations
- 🇮🇹
Federico II University Medical School, Naples, Italy
🇮🇹Istituto Nazionale per lo Studio e la Cura dei Tumori, Naples, Italy
🇮🇹Seconda Universita di Napoli, Naples, Italy
Liver Safety Under Upfront Arimidex vs Tamoxifen
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 384
- Registration Number
- NCT00537771
- Locations
- 🇨🇳
Research Site, Tianjin, China
Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer
- First Posted Date
- 2007-06-04
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 1
- Registration Number
- NCT00481845
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Partial Double-Blind, Placebo-Controlled Study to Assess the Effect of Anastrozole on the Endometrium in Healthy Volunteers
- First Posted Date
- 2007-04-30
- Last Posted Date
- 2009-06-03
- Lead Sponsor
- Meditrina Pharmaceuticals
- Target Recruit Count
- 64
- Registration Number
- NCT00467493
- Locations
- 🇺🇸
Jasper Research Clinic, Kalamazoo, Michigan, United States
🇺🇸University Women's Care, Southfield, Michigan, United States
Aromatase Inhibitors in the Treatment of Male Infertility
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 20
- Registration Number
- NCT00440180
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
Neoadjuvant Hormonal Treatment of Postmenopausal Women Who Have Operable Breast Cancer
- Conditions
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2007-02-21
- Lead Sponsor
- Instituto Nacional de Cancerologia de Mexico
- Target Recruit Count
- 30
- Registration Number
- NCT00437853
- Locations
- 🇲🇽
Instituto Nacional de Cancerologia de Mexico, Mexico D.F., Mexico, D.F., Mexico
Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2012-03-30
- Lead Sponsor
- Japan Breast Cancer Research Network
- Target Recruit Count
- 240
- Registration Number
- NCT00437359
- Locations
- 🇯🇵
The University of Tokyo Hospital, Tokyo, Japan
🇯🇵Shinyahashiradai Hospital, Matsudo, Japan
🇯🇵Nagumo Clinic, Tokyo, Japan
Insulin Sensitivity in Men With the Metabolic Syndrome
- Conditions
- Interventions
- Procedure: intravenous glucose tolerance testProcedure: aerobic capacity (VO2 Max)Drug: testosteroneProcedure: MRIDrug: goserelin acetate implantDrug: anastrozoleProcedure: muscle biopsyProcedure: measurement of resting metabolic rate (energy expenditure)Procedure: Dual energy x-ray absorptiometryProcedure: Fasting oral glucose tolerance test
- First Posted Date
- 2007-02-09
- Last Posted Date
- 2010-03-02
- Target Recruit Count
- 72
- Registration Number
- NCT00433173
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Bone Geometry and Muscle Density Changes in Postmenopausal Women and Breast Cancer Patients Prescribed Anastrozole
- First Posted Date
- 2007-01-12
- Last Posted Date
- 2015-09-23
- Lead Sponsor
- Hamilton Health Sciences Corporation
- Target Recruit Count
- 58
- Registration Number
- NCT00421447
- Locations
- 🇨🇦
McMaster University, Hamilton, Ontario, Canada
Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-11-30
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 79
- Registration Number
- NCT00405938
- Locations
- 🇺🇸
Sletten Cancer Institute, Great Falls, Montana, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.